No quarterly revenue total was found in MATINAS BIOPHARMA HOLDINGS, INC.'s SEC filings.
Matinas Biopharma Holdings, Inc. (MTNB) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $761,000 in cash and investments and $6,000 in total debt.
Revenue
—
Net income
$-1.33M
+74.7% vs year-ago quarter
Operating cash flow
$-1.84M
+9.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.21
+79.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
14.69M
+188.8% vs year-ago quarter
Net cash
$755,000
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MTNB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedminster, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1582554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.6M | -$1.9M | -$1.6M | -$1.6M | -$1.8M |
| Net income | -$1.3M | -$1.9M | -$1.9M | -$1.5M | -$5.2M |
| Diluted EPS | -$0.21 | -$0.30 | -$0.30 | -$0.40 | -$1.03 |
| Operating cash flow | -$1.8M | -$1.6M | -$1.5M | -$1.5M | -$2.0M |
| Total assets | $3.4M | $5.9M | $7.2M | $9.7M | $11.4M |
| Total liabilities | $1.6M | $2.9M | $2.4M | $3.2M | $3.7M |
| Stockholders' equity | $1.8M | $3.0M | $4.8M | $6.5M | $7.7M |
| Cash and investments | $761,000 | $2.4M | $4.0M | $5.4M | $6.5M |
| Total debt | $6,000 | $1.2M | $1.4M | $2.3M | $2.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Sep 4, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Agreement ended
|
Jul 24, 2026 | Jul 23, 2026 |
All 570 Matinas Biopharma Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.